Thromb Haemost 2005; 94(01): 53-59
DOI: 10.1160/TH05-02-0134
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

In vitro expression demonstrates impaired secretion of the γAsn319, Asp320 deletion variant fibrinogen

Satomi Kani
1   Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto Japan
,
Fumiko Terasawa
2   Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto Japan
,
Susan T. Lord
1   Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto Japan
,
Minoru Tozuka
1   Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto Japan
,
Hiroyoshi Ota
2   Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto Japan
,
Nobuo Okumura
2   Department of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto Japan
,
Tsutomu Katsuyama
1   Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto Japan
› Author Affiliations
Financial support: This work was partly supported by a Grant-in-Aid for Science Research from the Ministry of Education, Science and Culture of Japan (No.16590451, NO) and the US National Institutes of Health (R01 HL68836, STL).
Further Information

Publication History

Received 23 February 2005

Accepted after revision 09 April 2005

Publication Date:
05 December 2017 (online)

Summary

The hypodysfibrinogenemia Otsu is caused by the two-residue deletion,γAsn319 and γAsp320. Analysis of plasma or purified fibrinogen from the heterozygous propositus revealed that the amount of variant γ-chain was lower than that of normal γ-chain. In order to examine the basis for this difference, we transfected Chinese hamster ovary cells and established stable cell lines that expressed both chains, γΔ/γN, only the normal chain, γN, and only the variant chain, γΔ. We measured fibrinogen concentration of confluent cultures by ELISA. We found the ratios of the concentrations in the media to the concentrations in the cell lysates of γΔ, γΔ/γN, and γN-cells were 0.42, 0.60, and 1.00, respectively. We measured the concentrations of the γΔ and γN chains by densitometric analysis of samples following separation by SDS-PAGE and found the fraction of γΔ-chains in cell lysates was always greater than the fraction in the respective culture media. We examined the kinetics of fibrinogen synthesis, assembly and secretion in pulse-chase experiments, and found that the γΔ-chain was assembled into intact fibrinogen at a rate similar to assembly of the γN-chain into normal fibrinogen, but was secreted into the medium at a slightly slower rate than normal fibrinogen. Considered together, these experiments indicate secretion of the variant fibrinogen was slightly impaired. These results suggest that the reduced level of γΔ319,320 fibrinogen in the plasma of the Otsu patient arises from modestly impaired secretion of this variant fibrinogen.

 
  • References

  • 1 Blomback B. Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996; 83: 1-75.
  • 2 Doolittle RF. Fibrinogen and fibrin. Ann Rev Biochem 1984; 53: 195-229.
  • 3 Yu S, Sher B, Kudryk B. et al. Fibrinogen precursors. Order of assembly of fibrinogen chains. J Biol Chem 1984; 259: 10574-81.
  • 4 Huang S, Mulvihill ER, Farrell DH. et al. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in the assembly. J Biol Chem 1993; 268: 8919-26.
  • 5 Huang S, Cao Z, Chung DW. et al. The role of βγ and αγ complexes in the assembly of human fibrinogen. J Biol Chem 1996; 271: 27942-7.
  • 6 Redman CM, Xia H. Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion. Ann New York Acad Sci USA 2001; 936: 480-95.
  • 7 Okumura N, Terasawa F, Tanaka H. et al. Analysis of fibrinogen γ-chain truncations shows the C-terminus, particularly γIle387, is essential for assembly and se cretion of this multichain protein. Blood 2002; 99: 3654-60.
  • 8 http://www.geht.org/databaseang/fibrinogen/
  • 9 Brennan SO, Wyatt JM, May S. et al. Hypofibrinogenemia due to novel 316 Asp->Tyr substitution in the fibrinogen Bβ chain. Thromb Haemost 2001; 85: 450-3.
  • 10 Terasawa F, Okumura N, Kitano K. et al. Hypofibrinogenemia associated with a heterozygous missense mutation γ153Cys to Arg (Matsumoto IV): In vitro expression demonstrates defective secretion of the variant fibrinogen. Blood 1999; 94: 4122-31.
  • 11 Brennan SO, Wyatt J, Medicina D. et al. Fibrinogen Brescia. Hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a γ284 Gly->Arg mutation. Am J Pathol 2000; 157: 189-96.
  • 12 Brennan SO, Maghzal G, Shneider BL. et al. Novel fibrinogen γ375 Arg->Trp mutation (fibrinogen Aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36: 652-8.
  • 13 Brennan SO, Wyatt JM, Fellowes AP. et al. γ371 Thr->Ile substitution in the fibrinogen γD domain causes hypofibrinogenaemia. Biochim Biophys Acta 2001; 1550: 183-8.
  • 14 Maghzal GJ, Brennan SO, Fellows AP. et al. Familial hypofibrinogenemia associated with heterozygous substitution of a conserved arginine residue; Bβ255 Arg->His (fibrinogen Merivale). Biochim Biophys Acta 2003; 1645: 146-51.
  • 15 Duga S, Asselta R, Santagostino E. et al. Missense mutations in the β fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood 2000; 95: 1336-41.
  • 16 Spena S, Asselta O, Duga S. et al. Congenital afibrinogenemia: intracellular retention of fibrinogen due to a novel W437G mutation in the fibrinogen Bβ-chain gene. Biochim Biophys Acta 2003; 1639: 87-94.
  • 17 Vu D, Bolton-Maggs PHB, Parr JR. et al. Congenital afibrinogenemia: identification and expression of a missense mutation in FGB impairing fibrinogen secretion. Blood 2003; 102: 4413-5.
  • 18 Terasawa F, Hogan KA, Kani S. et al. Fibrinogen Otsu I: a γAsn319, γAsp320 deletion dysfibrinogen identified in an asymptomatic pregnant woman. Thromb Haemost 2003; 90: 757-8.
  • 19 Koopman J, Haverkate F, Briet E. et al. A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the γ-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 1991; 266: 13456-61.
  • 20 Hogan KA, Gorkun OV, Lounes KC. et al. Recombinant fibrinogen Vlissingen/Frankfurt IV. The deletion of residues 319 and 320 from the γ-chain of fibrinogen alters calcium binding, fibrin polymerization, crosslinking, and platelet aggregation. J Biol Chem 2000; 275: 17778-85.
  • 21 Okumura N, Furihata K, Terasawa F. et al. Fibrinogen Matsumoto II: γ308 Asn->Lys (AAT->AAG) mutation associated with bleeding tendency. Br J Haematol 1996; 94: 526-8.
  • 22 Okumura N, Gorkun OV, Lord ST. Severely impaired polymerization of recombinant fibrinogen γ-364 Asp-> His, the substitution discovered in a heterozygous individual. J Biol Chem 1997; 272: 29596-601.
  • 23 Mihalyi E. Physicochemical studies of bovine fibrinogen. IV. Ultraviolet absorption and its relation to the structure of the molecule. Biochemistry 1968; 7: 208-23.
  • 24 Hogan KA, Lord ST, Okumura N. et al. A functional assay suggests that heterodimers exist in two C-terminal γ-chain dysfibrinogens: Matsumoto I and Vlissingen/ Frankfurt IV. Thromb Haemost 2000; 83: 592-7.
  • 25 Binnie CG, Hettasch JM, Strickland E. et al. Characterization of purified recombinant fibrinogen: Partial phosphorylation of fibrinopeptide A. Biochemistry 1993; 32: 107-13.
  • 26 Hogan KA, Merenbloom BK, Kim HS. et al. Neonatal bleeding and decreased plasma fibrinogen levels in mice modeled after the dysfibrinogen Vlissingen/ Frankfurt IV. J Thromb Haemost 2004; 2: 1484-7.